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An elevated arterial pressure is an important health problem. There is a continuous
relationship between the level of blood pressure and the risk of cardiovascular and
renal target organ damage.''2 In most patients with arterial hypertension no
circumscript cause is present. These patients are said to have essential
hypertension. The primary difficulty in findlng the mechanism responsible for
essential hypertension is attributed to the variety of factors that are involved. There
is evidence that both environmental (salt intake, obesity, occupation etc) and
genetic factors contribute to the development of hypertension.
Several abnormalities have been described in essential hypertension that may be
primarily responsible for the hypertension. In particular, there is evidence for a
causal role of the kidney in essential hypertension. Renal transplantation studies in
animal models and humans demonstrate that "hypertension fol lows the kidney",  i .e.
implanting a kidney of a hypertensive subject in a normotensive subject will induce
hypertension and vice versa.3 The kidney plays a central role in the long-term
regulation of blood pressure and of sodium and volume homeostasis. This is
accomplished by an intricate interaction between multiple factors, which affect renal
sodium excretion and thereby regulate the effective circulating volume. These
factors may have a direct effect on sodium excretion by acting at a tubular level and
inhibiting sodium reabsorptron or indirectly by acting on renal hemodynamics.
In the 1970's i t  was recognized that dopamine, an intrarenal ly produced
hormone, is also an important regulator of renal function. lt became apparent that
dopamine has hemodynamic as well as tubular effects. The hemodynamic effects
include renal vasodilatation with a slight rise in glomerular filtration rate. The tubular
effects entail natriuresis and diuresis. Dopamine regulates renal function by
stimulation of specific renal dopaminergic receptors which are classified in two
groups, i.e., D,-like and Dr-like receptors.
Experimental and clinical studies suggest that defects in the renal dopaminergic
system, resulting in an impaired sodium and volume excretion, may play a role in
the pathogenesis of essential hypertension.a In patients with essential hypertension
a deficiency in renal dopamine synthesis andior secretion has been reported.s'6 In
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the Spontaneously Hypertensive Rat (SHR), an animal model of essential
hypertension, a defect in the tubular D,-like receptors has been associated with
impaired sodium handling.T However, it is unclear whether the renal hemodynamic
response to a D,-like receptor agonist is also impaired in SHRs. In addition, it is
unclear whether the defects in the dopaminergic system are limited to Dr-like
receptors or whether also a defect in the renal vascular response to a Dr-like
receptor agonist is Present.
The present thesis aims to elucidate whether in SHRs the renal hemodynamic
responses to a D,-like and Dr-like agonist are impaired. In vivo, the renal
hemodynamic response to dopaminergic stimulation may depend not only on the
function of the dopaminergic cascade as such, but also on interaction with other
neurohormonal systems. The interaction with the renin angiotensin aldosterone
system (RAAS) may be particularly relevant as renal vasoconstrictor responses to
angiotensin ll are enhanced in SHRs. We investigated the impact of this interaction
by studying the renal effects of dopaminergic stimulation during low and high
sodium intake thereby modifying the extent of RAAS activation in a physiological
way. Second, we studied the renal effects of dopaminergic stimulation during
pharmacological blockade of the AT1-receptor.
Chapter 1
To explore the effect of selective dopaminergic stimulation on renal hemodynamics
in the SHR, we first had to develop a model for measuring renal function in rats. In
small experimental animals renal function measurements by clearance methods are
often performed under anesthesia or with the application of restrainers and bladder
catheters, as these measurements rely on accurately timed and collected urine
samples. However, anesthesia and stress can affect renal function and bladder
catheters can give urinary tract infections, and bladder stones.s To avoid these
drawbacks we established a model for measuring renal function in conscious
unrestrained spontaneous voiding rats. Glomerular Filtration Rate (GFR) was
measured as the urinary clearance of constantly infused t'51-iothalamate. To correct
for incomplete bladcer emptying, a well-known problem in rats, urinary clearance of
"s1-iothalamate was multiplied by the ratio of plasma and urinary clearance of
140 Summary
simultaneously infused 13'l-hippuran. This correction method has previously been
validated in man.e
In chapter 1 we tested the feasibility of this renal function measurement
technique in rats with normal and moderately impaired renal function induced by
adriamycin. The intra-assay variation of the technique was evaluated by analysis of
the results of 4 consecutive clearance periods during the day. Furthermore we
evaluated the inter-assay variation by comparing clearance periods on separate
days in another group of rats. Application of the correction for voiding errors
significantly reduced the intra-assay coefficient of variation of GFR from 27.41 14.3
to 5.3 t 2.3 % in rats with normal renal function and from 27 .9 t 20.7 lo 2.7 ! 1.6 o/o
in rats with moderately impaired renal function. The inter-assay coefficient of
var iat ion fel l ,  a lbei t  not stat ist ical ly s igni f icant ( f rom 23.4 !  10.3 to 11.0 t  7.2o/o).
Our data show that this correction method is a useful technioue to assess renal
function in conscious, spontaneously voiding rats.
Chapter 2
A disadvantage of our method to measure GFR in conscious spontaneously voiding
rats is the requirement of an intra-arterial catheter for infusion of the renal function
tracers. Preparation of animals with chronic arterial catheters is difficult and may
increase mortality. Furthermore there is a high occlusion rate. We therefore tested
whether intraperitoneal infusion of t'ul-iothalamate and "1|-Hippuran can be used for
GFR measurement in conscious spontaneously voiding rats. We found that during
intraperitoneal administration stable plasma levels of tt' l-Hippuran could be
obtained. However, urinary recovery of l3l|-Hippuran was incomplete (66 t 32 %),
leading to a significant overestimation of GFR by 140 ! 13 % in comparison with
GFR measured by the intra-arterial technique. Thus, unfortunately the
intraperitoneal route of continuously infusion of renal function tracers cannot replace
intra-arterial infusion.
Chapter 3
We applied our method of renal function measurement to elucidate whether, in line
with the previously described impaired renal tubular dopaminergic responses, the
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renal hemodynamic responses to a D,-like and Dr-like agonist are impaired in the
SHR under normal physiological conditions. To date the few studies on the topic of
renal hemodynamic D,-like responsiveness in SHRs provide conflicting results,
which may be due to the use of anesthesia or due to the absence of control
groups.'ot'In chapter 3 we therefore compared the renal hemodynamic responses
to the continuously infused D,-like agonist fenoldopam in conscious SHR and in
normotensive Wistar Kyoto rats (WKY). In addition, we measured as an active
control the effects of the ACE inhibitor captopril. To exclude the possibility that the
observed effects of fenoldopam were related to the prevalent sodium status, we
studied the animals on a low as well as a high sodium diet.
We found that fenoldopam (2 pg/kg.min) significantly increased effective renal
plasma flow (ERPF) in WKY rcts (+22 ! 5 o ) whereas this response was absent in
SHRs (+7 ! 3 o/o, NS). Despite the absent increase in ERPF, fenoldopam
significantly lowered mean arterial pressure (MAP) in SHRs demonstrating a
systemic vasodilator esponse to fenoldopam in this strain. As a consequence, the
reduction in renal vascular resistance (RVR) was more pronounced in WKYs (-24 t
2o/o)than in SHRs (-13 t  4 %) (p<0.05).  The impaired renal vasodi lator esponse
was not due to impaired vasodilator capacity, as demonstrated by a significantly
ACE inhibi tor -  induced increase in ERPF in SHRs (+10 t  3 %, p<0.001).  The
blunting of the renal vasodilator esponse to fenoldopam in SHRs is independent of
sodium intake, as i t  was present dur ing a high as wel l  as a low sodium diet.  Thus,
the renal hemodynamic responses to the D,-like receptor agonist fenoldopam in
conscious SHRs are blunted under physiological conditions. The difference in renal
vasodilator esponse between SHR and WKY rats did not depend on sodium intake
and was not due to an impaired renal vasodilator capacity. Therefore, our findings
support the presence of a functional defect in the renal vascular dopaminergic
pathway in SHRs.
Chapter 4
Dopamine, the endogenous ligand, acts on both D,-like and Dr-like receptors. The
exact role of peripheral Dr-like receptors in the regulation of renal hemodynamics is
not clear. To date an increase as well as a decrease in ERPF and GFR in response
Summary
to Dr- l ike st imulat ion has been described. l2-14 These discrepancies may be due to
the use of anesthesia, different Dr-like agonists, and drfferences in route of
administration and differences in sodium status. We were especially interested
whether, similarly as the D,,-like renal vascular response, the renal vascular
response to a Dr-like receptor agonist is impaired in SHRs. To determine renal
hemodynamic responsiveness to Dr-like stimulation in SHRs we studied the effect
of a cont inuous infusion of the Dr- l ike agonist  N,N-Di-n-propyldopamine (DPDA) (10
pg/kg.min) on systemic and renal hemodynamics in conscious SHRs under low
sodium (LS) and high sodium (HS) condit ions as compared to the normotensive
WKY strain. The specificity of DPDA was tested by co-administration of the Dr-like
receptor antagonist domperidone. DPDA slightly reduced MAP in SHRs and in
WKYs under LS and HS condit ions. ERPF decreased to a simi lar extent in SHRs
( L S  - 2 0  ! 4 % ,  H S  - 2 0  t 2 % )  a n d  W K Y s  ( L S  - 1 4  ! 2 % ,  H S  - 1 7  t 2 o / o ) .  A s a
consequence, RVR increased significantly in both strains. The renal hemodynamic
response to DPDA was absent during pre-treatment with domperidone, indicating
the specificity of DPDA for the Dr-like receptors.
In conclusion, our data show a preserved Dr-mediated renal vasoconstriction in
SHRs. Thus, dur ing endogenous dopaminergic st imulat ion, the impaired D1-
mediated renal vasodilator along with the preserved Dr-mediated renal
vasoconstrictor response may result in renal vasoconstriction rather than
vasodilatation.
Chapter 5
The mechanism of the impaired renal vasodilator esponse to a D,-like agonist, as
described in chapter 3, is unclear.  The impaired response may be due to an
uncoupling of the D,-like receptor from the Gs-protein adenylyl cyclase enzyme
complex (its effector enzyme complex), a similar mechanism has been reported for
the renal tubular defect.ls On the other hand the blunted renal vasodilator action to
D,-like stimuli may be caused by an altered balance between the dopaminergic
system and renin angiotensin aldosterone system (RAAS). lt is well known that D,-
like stimulation induces renin release.t6't7 Activation of the RAAS by D,-like
st imulat ion may lead to an impaired renal vascular D,- l ike responsiveness in SHRs
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as there is evidence that the renal vasoconstrictor esponse to angiotensin ll is
more enhanced in SHR than in WKY rats,18 Therefore we were interested in the
renal hemodynamic responses to a D,-like receptor agonist in SHRs before and
after chronic blockade of the RAAS by an AT, receptor antagonist.
Fenoldopam reduced MAP to a comparable degree in WKYs and in SHRs. In
accordance with our previous findings, fenoldopam increased ERPF significantly
more in WKYs (+26 x 2 %) than in SHRs (+2 ! 2 %). Treatment with an AT,
receptor antagonist reduced MAP and increased ERPF and GFR significantly in
both strains. Pre-treatment with an AT, receptor antagonist induced a significant
increase in ERPF to fenoldopam in SHRs, but not in WKYs. As a result, during pre-
treatment with an AT., receptor antagonist, the rise in ERPF by fenoldopam was
s imi la r  in  bo th  s t ra ins  (SHR +25 t2%,  p  <  0 .0001 / WKY +33 +  2o /o ,  p  <  0 .0001) .
Thus, under physiological conditions, blockade of RAAS activity normalizes the
blunted renal vasodrlator esponse to a D,-like agonist in conscious SHRs. This
implies that the blunted vasodilator response is not due to a structural receptor
defect, or an impaired vasodilator capacity of renal vascular bed in SHRs, but to a
defective interaction between the dopaminergic system and the RAAS.
lmplications and future perspectives
Physiological, biochemical and molecular studies show the importance of
endogenous dopamine and renal dopamine receptors in the regulation of sodium
and body volume homeostasis. Several lines of evidence suggest that a defect in
the dopaminergic system is involved in the pathophysiology of hypertension. ln line
with the previously described D,-like receptor coupling defect in the proximal
tubules we found an impaired renal vasodilator response to a D,-like receptor
agonist in SHRs. This defect is present in the renal vascular bed and not in the
systemic vascular bed as we found a normal systemic vasodilator response during
D,-like stimulation. In addition, this defect in the dopaminergic system seems to be
limited to D,,-like receptors as we observed that the renal vasoconstrictor response
to a Dr-like receptor agonist is preserved in SHRs.
Dopamine, an intrarenal hormone, activates both dopaminergic receptor types
simultaneously and is mainly released under conditions of intravascular volume
